Endothelial function in HIV-infected persons

Clinical Infectious Diseases

Volumn 42, Issue 9, 2006, Pages 1325-1332

  Solages, Anthony ^a   Vita, Joseph A ^a   Thornton, David J ^a   Murray, Jessica ^b   Heeren, Timothy ^b   Craven, Donald E ^b,c   Horsburgh Jr , C Robert ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HIGH DENSITY LIPOPROTEIN TRIGLYCERIDE; HIGH DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ARM BLOOD FLOW; ARTICLE; BODY MASS; BRACHIAL ARTERY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SMOKING; VASODILATATION; VASOMOTOR REFLEX; VIRUS LOAD;

ADULT; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VASODILATION;

EID: 33646094737     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503261     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention. Update: trend in AIDS incidence, deaths, and prevalence-United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:165-73.
2. Concerted Action on SeroConversion to AIDS and Death in Europe Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE, HIV Med 2000; 1:224-31.
3. Hogg RS, O'Shaughnessy MV, O'Shaughnessy MV, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1294.
4. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336:1531-2.
5. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
6. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemias in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-5.
7. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-73.
8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
9. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-9.
10. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Diseases Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-27.
11. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
12. Passalaris J, Sekowitz K, Glesby M, et al. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31: 787-97.
13. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
14. Holmberg S, Moorman A, Williamson J, et al. Protease inhibitor and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-8.
15. Vittecoq D, Escaut L, Ghironi G, et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003; 17:570-6.
16. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-86.
17. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
18. Bozette SA, Ake CF, Tam HK, Chang SW Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-10.
19. Healy B. Endothelial cell dysfunction: an emerging endocrinopathy linked to coronary artery disease. J Am Coll Cardiol 1990; 16:357-8.
20. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106:640-2.
21. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
22. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105:1567-72.
23. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40:505-10.
24. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial functioning in the human coronary and peripheral circulation. J Am Coll Cardiol 1995; 26:1235-41.
25. Stein JH, Klein AK, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-62.
26. Dube MP, Shankar S, Vanderluitgaren JM, et al. Effect of indinavir monotherapy on endothelial function in men without HIV-infection. [abstract LB10]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:100.
27. Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM 2003; 96:825-32.
28. Gokce N, Holbrook M, Duffy SJ, et al. Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery. Hypertension 2001; 38:1349-54.
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421.
30. Vita JA. Nitric oxide-dependent vasodilation in human subjects. Methods Enzymol 2002; 359:186-200.
31. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community. The Framingham Heart Study. Circulation 2004; 109:613-19.
32. Laroia ST, Ganti A, Laroia AT, Tendulkar KK. Endothelium and the lipid metabolism: the current understanding. Int J Cardiol 2003; 88:1-9.
33. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10.
34. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993; 144:225-31.
35. Joshi VV, Pawel B, Conner E, et al. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 1987; 7:261-75.
36. Lafeuillade A, Alessi MC, Poizot-Martin, et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992; 5:127-31.
37. Blann AD, Constans J, Dignat-George F, Seigneur M. The platelet and endothelium in HIV infection. Br J Haematol 1998; 100:613-4.
38. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995; 90:244-8.
39. Zietz C, Hotz B, Sturzl M, Rauch E, Penning R, Lohrs U. Aortic endothelium in HIV-1 infection: chronic injury, activation, and increased leukocyte adherence. Am J Pathol 1996; 149:1887-98.
40. Seigneur M, Constans J, Blann A, et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997; 77:646-9.
41. de Larranaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 2003; 110:93-8.
42. Lange RA, Hillis D. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351-8.
43. Havranek EP, Nademanee K, Grayburn PA, Eichhorn EJ. Endothelium-dependent vasorelaxation is impaired in cocaine arteriopathy. J Am Coll Cardiol 1996; 28:1168-74.
44. Blum A, Hadas V, Burke M, Yust I, Kessler A. Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol 2005; 28:149-53.
45. Bozkurt B. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies. Cardiovasc Toxicol 2004; 4:243-60.
46. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147:E18.
47. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-73.